Emerging bacterial enzyme targets

Current Opinion in Investigational Drugs

Volumn 8, Issue 2, 2007, Pages 140-149

  Su, Zhengding ^a   Honek, John F ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Antibacterial; Cell wall biosynthesis; Drug discovery; Drug resistance; Enzyme; Fatty acid biosynthesis; Inhibitor

Indexed keywords

ANDRIMID; ANTIINFECTIVE AGENT; CERULENIN; CORYTUBERINE; HEXACHLOROPHENE; MOIRAMIDE B; PHOMALLENIC ACID C; PLATENSIMYCIN; THIOLACTOMYCIN; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; BIOSYNTHESIS; CELL WALL; FATTY ACID SYNTHESIS; GENE TARGETING; NONHUMAN; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; TECHNOLOGY, PHARMACEUTICAL;

EID: 33947309695     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Furuya EY, Lowy FD: Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol (2006) 4(1):36-45.
2. Levin BR, Rozen DE: Non-inherited antibiotic resistance. Nat Rev Microbiol (2006) 4(7):556-562.
3. Projan SJ: Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol (2003) 6(5):427-430.
4. Theuretzbacher U, Toney JH: Nature's clarion call of antibacterial resistance: Are we listening? Curr Opin Investig Drugs (2006) 7(2):158-166.
5. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: A new adaptation of a common aminoglycoside acetyltransferase. Nat Med (2006) 12(1):83-88. •• This paper reports reduced susceptibility to ciprofloxacin in clinical bacterial isolates conferred by a variant of the gene encoding aminoglycoside acetyltransferase AAC(6′)-Ib.
6. Seedat J, Zick G, Klare I, Konstabel C, Weiler N, Sahly H: Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob Agents Chemother (2006) 50(12):4217-4219.
7. Rice SA, McDougald D, Kumar N, Kjelleberg S: The use of quorum-sensing blockers as therapeutic agents for the control of biofilm-associated infections. Curr Opin Investig Drugs (2005) 6(2):178-184.
8. Breukink E, de Kruijff B: Lipid II as a target for antibiotics. Nat Rev Drug Discov (2006) 5(4):321-332.
9. Kaatz GW: Bacterial efflux pump inhibition. Curr Opin Investig Drugs (2005) 6(2):191-198.
10. Stephenson K, Hoch JA: Developing inhibitors to selectively target two-component and phosphorelay signal transduction systems of pathogenic microorganisms. Curr Med Chem (2004) 11(6):765-773.
11. Robertson JG: Mechanistic basis of enzyme-targeted drugs. Biochemistry (2005) 44(15):5561-5571. • A good, general review on the variety of inhibition mechanisms for enzyme-targeted drugs. Data are based on 317 marketed drugs that function by inhibiting an enzyme.
12. Zhang YM, White SW, Rock CO: Inhibiting bacterial fatty acid synthesis. J Biol Chem (2006) 281(26):17541-17544. •• An excellent mini-review highlighting the importance of enzymes of bacterial FAB in antibacterial drug discovery.
13. Campbell JW, Cronan JE Jr: Bacterial fatty acid biosynthesis: Targets for antibacterial drug discovery. Annu Rev Microbiol (2001) 55:305-332. • A comprehensive review of the bacterial FAB pathway. This review discusses the known inhibitors identified before 2001.
14. White SW, Zheng J, Zhang YM, Rock CO: The structural biology of type II fatty acid biosynthesis. Annu Rev Biochem (2005) 74:791-831. •• A comprehensive and up-to-date review of the structures of enzymes involved in bacterial FAB and their implication in antibacterial agent discovery.
15. Cronan JE: Bacterial membrane lipids: Where do we stand? Annu Rev Microbiol (2003) 57:203-224.
16. Tong L, Harwood HJ Jr: Acetyl-coenzyme A carboxylases: Versatile targets for drug discovery. J Cell Biochem (2006) 99(6):1476-1488.
17. Tong L: Acetyl-coenzyme A carboxylase: Crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci (2005) 62(16):1784-1803.
18. Zhang H, Tweel B, Tong L: Molecular basis for the inhibition of the carboxyltransferase domain of acetyl-coenzyme-A carboxylase by haloxyfop and diclofop. Proc Natl Acad Sci USA (2004) 101(16):5910-5915.
19. Nikolskaya T, Zagnitko O, Tevzadze G, Haselkorn R, Gornicki P: Herbicide sensitivity determinant of wheat plastid acetyl-CoA carboxylase is located in a 400-amino acid fragment of the carboxyltransferase domain. Proc Natl Acad Sci USA (1999) 96(25):14647-14651.
20. Lin TW, Melgar MM, Kurth D, Swamidass SJ, Purdon J, Tseng T, Gago G, Baldi P, Gramajo H, Tsai SC: Structure-based inhibitor design of AccD5, an essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium tuberculosis. Proc Natl Acad Sci USA (2006) 103(9):3072-3077.
21. James ES, Cronan JE: Expression of two Escherichia coli acetyl-CoA carboxylase subunits is autoregulated. J Biol Chem (2004) 279(4):2520-2527.
22. Jin M, Fischbach MA, Clardy J: A biosynthetic gene cluster for the acetyl-CoA carboxylase inhibitor andrimid. J Am Chem Soc (2006) 128(33):10660-10661. •• The andrimid biosynthetic gene cluster from Pantoea agglomerans was cloned in E coli and the system enabled production of a diverse set of andrimid analogs for future clinical evaluation.
23. Freiberg C, Brunner NA, Schiffer G, Lampe T, Pohlmann J, Brands M, Raabe M, Habich D, Ziegelbauer K: Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J Biol Chem (2004) 279(25):26066-26073. • This paper describes the mode of action of natural product-derived pyrrolidinediones. These compounds represent the first bacterial ACCase inhibitors with antibacterial activity.
24. Pohlmann J, Lampe T, Shimada M, Nell PG, Pernerstorfer J, Svenstrup N, Brunner NA, Schiffer G, Freiberg C: Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action. Bioorg Med Chem Lett (2005) 15(4):1189-1192.
25. Bilder P, Lightle S, Bainbridge G, Ohren J, Finzel B, Sun F, Holley S, Al Kassim L, Spessard C, Melnick M, Newcomer M, Waldrop GL: The structure of the carboxyltransferase component of acetyl-coA carboxylase reveals a zinc-binding motif unique to the bacterial enzyme. Biochemistry (2006) 45(6):1712-1722.
26. Santoro N, Brtva T, Roest SV, Siegel K, Waldrop GL: A high-throughput screening assay for the carboxyltransferase subunit of acetyl-CoA carboxylase. Anal Biochem (2006) 354(1):70-77.
27. Soriano A, Radice AD, Herbitter AH, Langsdorf EF, Stafford JM, Chan S, Wang S, Liu YH, Black TA: Escherichia coli acetyl-coenzyme A carboxylase: Characterization and development of a high-throughput assay. Anal Biochem (2006) 349(2):268-276.
28. Liu W, Han C, Hu L, Chen K, Shen X, Jiang H: Characterization and inhibitor discovery of one novel malonyl-CoA: Acyl carrier protein transacylase (MCAT) from Helicobacter pylori. FEBS Lett (2006) 580(2):697-702.
29. Oefner C, Schulz H, D'Arcy A, Dale GE: Mapping the active site of Escherichia coli malonyl-CoA-acyl carrier protein transacylase (FabD) by protein crystallography. Acta Crystallogr D Biol Crystallogr (2006) 62(6):613-618.
30. He X, Reynolds KA: Purification, characterization, and identification of novel inhibitors of the β-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus. Antimicrob Agents Chemother (2002) 46(5):1310-1318.
31. He X, Reeve AM, Desai UR, Kellogg GE, Reynolds KA: 1,2-Dithiole-3-ones as potent inhibitors of the bacterial 3-ketoacyl acyl carrier protein synthase III (FabH). Antimicrob Agents Chemother (2004) 48(8):3093- 3102.
32. Ashek A, Cho SJ: A combined approach of docking and 3D QSAR study of β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors. Bioorg Med Chem (2006) 14(5):1474-1482.
33. Musayev F, Sachdeva S, Scarsdale JN, Reynolds KA, Wright HT: Crystal structure of a substrate complex of Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein synthase III (FabH) with lauroyl-coenzyme A. J Mol Biol (2005) 346(5):1313-1321.
34. Nie Z, Perretta C, Lu J, Su Y, Margosiak S, Gajiwala KS, Cortez J, Nikulin V, Yager KM, Appelt K, Chu S: Structure-based design, synthesis, and study of potent inhibitors of β-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. J Med Chem (2005) 48(5):1596-1609.
35. Wickramasinghe SR, Inglis KA, Urch JE, Muller S, van Aalten DM, Fairlamb AH: Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis. Biochem J (2006) 393(2):447-457.
36. Kimber MS, Martin F, Lu Y, Houston S, Vedadi M, Dharamsi A, Fiebig KM, Schmid M, Rock CO: The structure of (3R)-hydroxyacyl-acyl carrier protein dehydratase (FabZ) from Pseudomonas aeruginosa. J Biol Chem (2004) 279(50):52593-52602.
37. Lu YJ, White SW, Rock CO: Domain swapping between Enterococcus faecalis FabN and FabZ proteins localizes the structural determinants for isomerase activity. J Biol Chem (2005) 280(34):30342- 30348.
38. Liu W, Du L, Zhang L, Chen J, Shen X, Jiang H: Helicobacter pylori acyl carrier protein: Expression, purification, and its interaction with β-hydroxyacyl-ACP dehydratase. Protein Expr Purif (2007) 52(1):74-81.
39. Ling LL, Xian J, Ali S, Geng B, Fan J, Mills DM, Arvanites AC, Orgueira H, Ashwell MA, Carmel G, Xiang Y, Moir DT: Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob Agents Chemother (2004) 48(5):1541-1547.
40. Rafi S, Novichenok P, Kolappan S, Zhang X, Stratton CF, Rawat R, Kisker C, Simmerling C, Tonge PJ: Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli. J Biol Chem (2007) 281(51):39285-39293.
41. Saito J, Yamada M, Watanabe T, Kitagawa H, Takeuchi Y: Crystallization and preliminary X-ray analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae. Acta Crystallograph Sect F Struct Biol Cryst Commun (2006) 62(6):576-578.
42. Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf WE Jr, Fosberry AP, Greenwood R, Head MS, Heerding DA et al: Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob Agents Chemother (2002) 46(10):3118-3124.
43. Oliveira JS, de Sousa EH, de Souza ON, Moreira IS, Santos DS, Basso LA: Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex. Curr Pharm Des (2006) 12(19):2409-2424.
44. Ondeyka JG, Zink DL, Young K, Painter R, Kodali S, Galgoci A, Collado J, Tormo JR, Basilio A, Vicente F, Wang J, Singh SB: Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy. J Nat Prod (2006) 69(3):377-380. •• This paper reports the discovery of phomallenic acids from a leaf litter fungus of Phoma sp as antibacterial inhibitors using a new, selective and highly sensitive whole cell-based antisense strategy.
45. Young K, Jayasuriya H, Ondeyka JG, Herath K, Zhang C, Kodali S, Galgoci A, Painter R, Brown-Driver V, Yamamoto R, Silver LL et al: Discovery of FabH/FabF inhibitors from natural products. Antimicrob Agents Chemother (2006) 50(2):519-526. • The natural product phomallenic acid C exhibited good antibacterial activity (approximately 20-fold superior to that of thiolactomycin and cerulenin) against S aureus and demonstrated a spectrum of antibacterial activity against clinically important pathogens, including methicillin-resistant S aureus, B subtilis and H influenzae.
46. Price AC, Rock CO, White SW: The 1.3-Angstrom-resolution crystal structure of β-ketoacyl-acyl carrier protein synthase II from Streptococcus pneumoniae. J Bacteriol (2003) 185(14):4136-4143.
47. Kim P, Zhang YM, Shenoy G, Nguyen QA, Boshoff HI, Manjunatha UH, Goodwin MB, Lonsdale J, Price AC, Miller DJ, Duncan K et al: Structure- activity relationships at the 5-position of thiolactomycin: An intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli. J Med Chem (2006) 49(1):159-171.
48. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R, Parthasarathy G, Tang YS, Cummings R, Ha S et al: Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature (2006) 441(7091):358-361. •• This paper reports the discovery of platensimycin, a novel inhibitor with a unique mode of action that is selective against FabF/B in the synthetic pathway of fatty acids. Platensimycin is the most potent inhibitor reported for the FabF/B condensing enzymes, and is the only inhibitor of these targets that demonstrated broad-spectrum activity, in vivo efficacy and no observable toxicity.
49. Singh SB, Jayasuriya H, Ondeyka JG, Herath KB, Zhang C, Zink DL, Tsou NN, Ball RG, Basilio A, Genilloud O, Diez MT et al: Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. J Am Chem Soc (2006) 128(36):11916-11920.
50. Takayama K, Wang C, Besra GS: Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin Microbiol Rev (2005) 18(1):81-101. • A review describing the detailed pathway of mycolic acid biosynthesis in M tuberculosis. This paper highlights the potential of targeting enzymes within this pathway for new drug discovery.
51. Takayama K, Hayes B, Vestling MM, Massey RJ: Transposon-5 mutagenesis transforms Corynebacterium matruchotii to synthesize novel hybrid fatty acids that functionally replace corynomycolic acid. Biochem J (2003) 373(2):465-474.
52. Bhatt A, Kremer L, Dai AZ, Sacchettini JC, Jacobs WR Jr: Conditional depletion of KasA, a key enzyme of mycolic acid biosynthesis, leads to mycobacterial cell lysis. J Bacteriol (2005) 187(22):7596- 7606.
53. Bhakta S, Besra GS, Upton AM, Parish T, Sholto-Douglas-Vernon C, Gibson KJ, Knutton S, Gordon S, DaSilva RP, Anderton MC, Sim E: Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. J Exp Med (2004) 199(9):1191-1199.
54. Scheffers DJ, Pinho MG: Bacterial cell wall synthesis: New insights from localization studies. Microbiol Mol Biol Rev (2005) 69(4):585-607.
55. Stewart GC: Taking shape: Control of bacterial cell wall biosynthesis. Mol Microbiol (2005) 57(5):1177-1181.
56. Katz AH, Caufield CE: Structure-based design approaches to cell wall biosynthesis inhibitors. Curr Pharm Des (2003) 9(11):857-866.
57. Eschenburg S, Priestman MA, Abdul-Latif FA, Delachaume C, Fassy F, Schonbrunn E: A novel inhibitor that suspends the induced fit mechanism of UDP-N-acetylglucosamine enolpyruvyl transferase (MurA). J Biol Chem (2005) 280(14):14070-14075.
58. Molina-Lopez J, Sanschagrin F, Levesque RC: A peptide inhibitor of MurA UDP-N-acetylglucosamine enolpyruvyl transferase: The first committed step in peptidoglycan biosynthesis. Peptides (2006) 27(12):3115-3121.
59. Yang Y, Severin A, Chopra R, Krishnamurthy G, Singh G, Hu W, Keeney D, Svenson K, Petersen PJ, Labthavikul P, Shlaes DM et al: 3,5-Dioxopyrazolidines, novel inhibitors of UDP-N- acetylenolpyruvylglucosamine reductase (MurB) with activity against Grampositive bacteria. Antimicrob Agents Chemother (2006) 50(2):556-564.
60. Xu HH, Real L, Bailey MW: An array of Escherichia coli clones overexpressing essential proteins: A new strategy of identifying cellular targets of potent antibacterial compounds. Biochem Biophys Res Commun (2006) 349(4):1250-1257.
61. Gilbert AM, Failli A, Shumsky J, Yang Y, Severin A, Singh G, Hu W, Keeney D, Petersen PJ, Katz AH: Pyrazolidine-3,5-diones and 5-hydroxy-1 H-pyrazol-3(2H)-ones, inhibitors of UDP-N-acetylenolpyruvyl glucosamine reductase. J Med Chem (2006) 49(20):6027-6036.
62. Smith CA: Structure, function and dynamics in the Mur family of bacterial cell wall ligases. J Mol Biol (2006) 362(4):640-655. • This paper describes a detailed comparison of the structure-function relationships of four Mur enzymes.
63. Baum EZ, Crespo-Carbone SM, Abbanat D, Foleno B, Maden A, Goldschmidt R, Bush K: Utility of muropeptide ligase for identification of inhibitors of the cell wall biosynthesis enzyme MurF. Antimicrob Agents Chemother (2006) 50(1):230-236.
64. Longenecker KL, Stamper GF, Hajduk PJ, Fry EH, Jakob CG, Harlan JE, Edalji R, Bartley DM, Walter KA, Solomon LR, Holzman TF et al: Structure of MurF from Streptococcus pneumoniae co-crystallized with a small molecule inhibitor exhibits interdomain closure. Protein Sci (2005) 14(12):3039-3047.
65. Comess KM, Schurdak ME, Voorbach MJ, Coen M, Trumbull JD, Yang H, Gao L, Tang H, Cheng X, Lerner CG, McCall JO et al: An ultraefficient affinity-based high-throughout screening process: Application to bacterial cell wall biosynthesis enzyme MurF. J Biomol Screen (2006) 11(7):743-754.
66. Stamper GF, Longenecker KL, Fry EH, Jakob CG, Florjancic AS, Gu YG, Anderson DD, Cooper CS, Zhang T, Clark RF, Cia Y et al: Structure-based optimization of MurF inhibitors. Chem Biol Drug Des (2006) 67(1):58-65.
67. Paradis-Bleau C, Beaumont M, Boudreault L, Lloyd A, Sanschagrin F, Bugg TD, Levesque RC: Selection of peptide inhibitors against the Pseudomonas aeruginosa MurD cell wall enzyme. Peptides (2006) 27(7):1693-1700.
68. Bugg TD, Lloyd AJ, Roper DI: Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins. Infect Disord Drug Targets (2006) 6(2):85-106.
69. Dini C: MraY inhibitors as novel antibacterial agents. Curr Top Med Chem (2005) 5(13):1221-1236.
70. Solapure SM, Raphael P, Gayathri CN, Barde SP, Chandrakala B, Das KS, De Sousa SM: Development of a microplate-based scintillation proximity assay for MraY using a modified substrate. J Biomol Screen (2005) 10(2):149-156.
71. Ueda T, Feng F, Sadamoto R, Niikura K, Monde K, Nishimura S: Synthesis of 4-fluorinated UDP-MurNAc pentapeptide as an inhibitor of bacterial growth. Org Lett (2004) 6(11):1753-1756.
72. Lloyd AJ, Brandish PE, Gilbey AM, Bugg TD: Phospho-N- acetylmuramyl-pentapeptide translocase from Escherichia coli: Catalytic role of conserved aspartic acid residues. J Bacteriol (2004) 186(6):1747-1757.
73. Bouhss A, Crouvoisier M, Blanot D, Mengin-Lecreulx D: Purification and characterization of the bacterial MraY translocase catalyzing the first membrane step of peptidoglycan biosynthesis. J Biol Chem (2004) 279(29):29974-29980.
74. Kruger RG, Otvos B, Frankel BA, Bentley M, Dostal P, McCafferty DG: Analysis of the substrate specificity of the Staphylococcus aureus sortase transpeptidase SrtA. Biochemistry (2004) 43(6):1541-1551.
75. Oh KB, Oh MN, Kim JG, Shin DS, Shin J: Inhibition of sortase-mediated Staphylococcus aureus adhesion to fibronectin via fibronectin-binding protein by sortase inhibitors. Appl Microbiol Biotechnol (2006) 70(1):102-106.
76. Oh KB, Mar W, Kim S, Kim JY, Oh MN, Kim JG, Shin D, Sim CJ, Shin J: Bis(indole) alkaloids as sortase A inhibitors from the sponge Spongosorites sp. Bioorg Med Chem Lett (2005) 15(22):4927-4931.
77. Paterson GK, Mitchell TJ: The role of Streptococcus pneumoniae sortase A in colonisation and pathogenesis. Microbes Infect (2006) 8(1):145-153.
78. Yamaguchi M, Terao Y, Ogawa T, Takahashi T, Hamada S, Kawabata S: Role of Streptococcus sanguinis sortase A in bacterial colonization. Microbes Infect (2006) 8(12-13):2791-2796.
79. Pillai B, Cherney MM, Diaper CM, Sutherland A, Blanchard JS, Vederas JC, James MN: Structural insights into stereochemical inversion by diaminopimelate epimerase: An antibacterial drug target. Proc Natl Acad Sci USA (2006) 103(23):8668-8673. •• This report describes the crystal structures of DAP epimerase in complex with diastereomers of DAP irreversibly bound in the active site, providing a detailed picture of the mechanism of action of pyridoxal 5′-phosphate-independent racemases, which are potential antibacterial targets.
80. Besong GE, Bostock JM, Stubbings W, Chopra I, Roper DI, Lloyd AJ, Fishwick CW, Johnson AP: A de novo designed inhibitor of D-Ala-D-Ala ligase from E. coli. Angew Chem Int Ed Engl (2005) 44(39):6403-6406.
81. May JJ, Finking R, Wiegeshoff F, Weber TT, Bandur N, Koert U, Marahiel MA: Inhibition of the D-alanine:D-alanyl carrier protein ligase from Bacillus subtilis increases the bacterium's susceptibility to antibiotics that target the cell wall. FEBS J (2005) 272(12):2993-3003.
82. Liu S, Chang JS, Herberg JT, Horng MM, Tomich PK, Lin AH, Marotti KR: Allosteric inhibition of Staphylococcus aureus D-alanine:D-alanine ligase revealed by crystallographic studies. Proc Natl Acad Sci USA (2006) 103(41):15178-15183. • This paper reports the crystal structure of S aureus DDl (StaDDl) and its cocrystal structures with 3-chloro-2,2-dimethyl-N-[4(trifluoromethyl) phenyl] propanamide and ADP. An allosteric inhibition mechanism of StaDDl by this compound is proposed.
83. Alderwick LJ, Seidel M, Sahm H, Besra GS, Eggeling L: Identification of a novel arabinofuranosyltransferase (AftA) involved in cell wall arabinan biosynthesis in Mycobacterium tuberculosis. J Biol Chem (2006) 281(23):15653-15661.
84. Alderwick LJ, Radmacher E, Seidel M, Gande R, Hitchen PG, Morris HR, Dell A, Sahm H, Eggeling L, Besra GS: Deletion of Cg-emb in Corynebacterianeae leads to a novel truncated cell wall arabinogalactan, whereas inactivation of Cg-ubiA results in an arabinan-deficient mutant with a cell wall galactan core. J Biol Chem (2005) 280(37):32362-32371.
85. Kantardjieff KA, Kim CY, Naranjo C, Waldo GS, Lekin T, Segelke BW, Zemla A, Park MS, Terwilliger TC, Rupp B: Mycobacterium tuberculosis RmlC epimerase (Rv3465): A promising drug-target structure in the rhamnose pathway. Acta Crystallogr D Biol Crystallogr (2004) 60(5):895-902.
86. Monaghan RL, Barrett JF: Antibacterial drug discovery - then, now and the genomics future. Biochem Pharmacol (2006) 71(7):901-909.
87. Freiberg C, Brotz-Oesterhelt H: Functional genomics in antibacterial drug discovery. Drug Discov Today (2005) 10(13):927-935.
88. Brotz-Oesterhelt H, Bandow JE, Labischinski H: Bacterial proteomics and its role in antibacterial drug discovery. Mass Spectrom Rev (2005) 24(4):549-565.
89. Chan PF, Macarron R, Payne DJ, Zalacain M, Holmes DJ: Novel antibacterials: A genomics approach to drug discovery. Curr Drug Targets Infect Disord (2002) 2(4):291-308.
90. Miesel L, Greene J, Black TA: Genetic strategies for antibacterial drug discovery. Nat Rev Genet (2003) 4(6):442-456.
91. Hawser SP: Antibacterial Drug Discovery and Development - SRI's 11th Annual Summit. IDrugs (2006) 9(6):390-393.
92. Silver LL: Antibacterial Drug Discovery and Development - SRI's 11th Annual Summit. Antibacterial Trends and Current Research. IDrugs (2006) 9(6):394-397.
93. Lynch AS: Antibacterial Drug Discovery and Development Summit - Tenth Annual SRI Summit. IDrugs (2005) 8(5):395-398.
94. Bryant PA, Venter D, Robins-Browne R, Curtis N: Chips with everything: DNA microarrays in infectious diseases. Lancet Infect Dis (2004) 4(2):100-111.
95. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE III: The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: Novel insights into drug mechanisms of action. J Biol Chem (2004) 279(38):40174-40184.
96. Bandow JE, Brotz H, Leichert LI, Labischinski H, Hecker M: Proteomic approach to understanding antibiotic action. Antimicrob Agents Chemother (2003) 47(3):948-955.
97. Orchard S, Hermjakob H, Apweiler R: The proteomics standards initiative. Proteomics (2003) 3(7):1374-1376.
98. Hermjakob H, Montecchi-Palazzi L, Bader G, Wojcik J, Salwinski L, Ceol A, Moore S, Orchard S, Sarkans U, von Mering C, Roechert B et al: The HUPO PSI's molecular interaction format - a community standard for the representation of protein interaction data. Nat Biotechnol (2004) 22(2):177-183.
99. Ji Y, Yin D, Fox B, Holmes DJ, Payne D, Rosenberg M: Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. FEMS Microbiol Lett (2004) 231(2):177-184.
100. Marra A: Targeting virulence for antibacterial chemotherapy: Identifying and characterising virulence factors for lead discovery. Drugs R D (2006) 7(1):1-16.
101. Coates AR, Hu Y: New strategies for antibacterial drug design: Targeting non-multiplying latent bacteria. Drugs R D (2006) 7(3):133-151.
102. Fischer HP, Brunner NA, Wieland B, Paquette J, Macko L, Ziegelbauer K, Freiberg C: Identification of antibiotic stress-inducible promoters: A systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery. Genome Res (2004) 14(1):90-98.
103. Barker JJ: Antibacterial drug discovery and structure-based design. Drug Discov Today (2006) 11(9-10):391-404.
104. Singh SB, Barrett JF: Empirical antibacterial drug discovery - foundation in natural products. Biochem Pharmacol (2006) 71(7):1006-1015.
105. Leeds JA, Schmitt EK, Krastel P: Recent developments in antibacterial drug discovery: Microbe-derived natural products - from collection to the clinic. Expert Opin Invest Drugs (2006) 15(3):211-226.
106. OSCIENT PHARMACEUTICALS; ARQULE INC (Moir DT, Xiang Y, Arvanites AC, Ali SM, Geng B, Ashwell MA, Orgueira HA): Antibacterial Fab I inhibitors. WO-2004064837 (2004).
107. AFFINIUM PHARMACEUTICALS INC (Berman J, Sampson P, Pauls HW, Ramnauth J, Manning DD, Surman MD, Xie D, Decornez HY): Heterocyclic compounds, methods of making them and their use in therapy. WO-2004052890 (2004).
108. AFFINIUM PHARMACEUTICALS INC (Burgess WJ, Jakas D, Huffman WF, Miller WH, Newlander KA, Seefeld MA, Uzinskas IN): Fab I inhibitors. WO-2003088897 (2003).
109. COLUMBIA UNIVERSITY; ALBERT EINSTEIN COLLEGE OF MEDICINE (Kabbash C, Silverstein SC, Shuman HA, Blanchard JS): Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof. US-06531291 (2003).
110. SMITHKLINE BEECHAM CORP (Miller WH, Newlander KA, Seefeld MA): Fab I inhibitors. WO-2001026654 (2001).
111. SMITHKLINE BEECHAM CORP (Miller WH, Newlander KA, Seefeld MA, Uzinskas IN): Fab I inhibitors. WO-2001026652 (2001).
112. SMITHKLINE BEECHAM CORP (Miller WH, Newlander KA, Seefeld M): Antibacterial compounds. WO-2000072846 (2000).
113. SMITHKLINE BEECHAM CORP (Miller WH, Newlander KA, Seefeld MA): Fab I inhibitors. WO-2000063187 (2000).
114. SMITHKLINE BEECHAM CORP (Daines RA, Pendrak I): Fatty acid synthase inhibitors. WO-2002024197 (2002).
115. SMITHKLINE BEECHAM CORP (Christensen SB, Mercer DJ, Xiang J-N): Fatty acid synthase inhibitors. WO-2002009688 (2002).
116. SMITHKLINE BEECHAM CORP (Xiang J-N, Christensen SB, Mercer DJ): Fatty acid synthase inhibitors. WO-2002002119 (2002).
117. SMITHKLINE BEECHAM CORP (Daines RA, Pendrak I): Fatty acid synthase inhibitors. WO-2002000646 (2002).
118. SMITHKLINE BEECHAM CORP (Leber JD, Christensen SB, Daines RA, LI M, Weinstock J, Head MS): Fatty acid synthase inhibitors. WO-2001090099 (2001).
119. SMITHKLINE BEECHAM CORP (Gaitanopoulos D, Leber JD, Li M, Weinstock J): Fatty acid synthase inhibitors. WO-2001014364 (2001).
120. SMITHKLINE BEECHAM CORP (Daines RA, Chan GW, Sham KKC): Indole compounds. WO-2001030752 (2001).
121. SMITHKLINE BEECHAM CORP (Daines RA, Kingsbury WD, Pendrak I): Novel indole compounds. WO-2001030775 (2001).
122. SMITHKLINE BEECHAM CORP (Christensen SB, Daines RA, Leber JD, Weinstock J): Fatty acid synthase inhibitors. WO-2001014362 (2001).
123. SMITHKLINE BEECHAM CORP (Daines RA, Christensen SB, Leber JD, Head MS): Fatty acid synthase inhibitors. WO-2002000620 (2002).
124. SMITHKLINE BEECHAM CORP (Daines RA, Sham KC): Indole compounds. WO-2000078309 (2000).
125. WYETH (Caufield CE, Antane SA, Morris KM, Naughton SM, Quagliato DA, Andrae PM, Enos A, Chiarello JF): 3-Aryl-4-hydroxyfuranone compounds and pharmaceutical and veterinary compositions containing them. WO-2005019196 (2005).
126. Maletic MM, Leeman AH, Santorelli GM, Waddell ST: Muramic acid derivative compounds. US-2004028702 (2004).
127. PLIVA DD; ESSENTIAL THERAPEUTICS INC (Moe ST, Ala PJ, Perola E, Faerman CH, Clement JJ, Ali JA, Will PM, Marchese SA, Magee AS, Gazzaniga JV, Farady C, Navia MA, Connelly PR): 8/17 Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors. WO-2003001887 (2003).
128. Kahne SW, Kahne D: Identification of active-site of glycosyltransferases using a generalizable high-throughput screen. US-20050142629 (2005).